Market evolution: Medical implants (CN 90213990) — 2015–2025

Introduction

This report analyses the evolution of European Union trade in Artificial parts of the body (CN 90213990) over the period 2015–2025. This product category covers a wide range of medical implants — including cardiac stents, cochlear implants, vascular grafts, and other prosthetic devices — but explicitly excludes artificial teeth, dental fittings, artificial joints, and ocular prostheses. The period under review witnessed substantial structural shifts: the EU transformed from a net importer into a net exporter, trade volumes and values grew significantly, and the geographic landscape of trade was reshaped by the emergence of new partners and the reconfiguration of established relationships.

1. From deficit to balance: The EU's transformation into a net exporter

1.1 The headline figures show converging export and import trajectories

Between 2015 and 2025, EU exports of artificial body parts grew by 79.4% in value, rising from €1.48 billion to €2.66 billion. Over the same period, imports increased by 59.5%, from €1.67 billion to €2.66 billion. By 2025, exports and imports had virtually converged in value terms — a remarkable shift from the €184.5 million trade deficit recorded at the beginning of the period.

1.2 Divergent volume and price dynamics underlie the headline convergence

A closer look at quantity and price reveals a striking divergence. Export quantities grew by 45.7% (from 2,096 to 3,054 tonnes), while import quantities fell by 16.2% (from 2,237 to 1,875 tonnes). This means that the EU has been importing fewer tonnes of implants while exporting more — a pattern consistent with a maturing domestic industry that increasingly serves both home and foreign markets.

1.3 Soaring import unit values suggest a shift in the composition of imports

The most revealing figure is the 90.3% increase in the import unit price (from €744,238 to €1,416,137 per tonne) — nearly four times the rise in export unit values (+23.2%). This suggests that while the EU is importing less in volume, the products it sources from outside have become significantly more expensive per unit of weight. This could reflect a shift towards higher-value, more specialised implant technologies (e.g., advanced cardiac devices or neural implants), or rising input costs in key supplier countries. Either way, it indicates that the EU's import basket has moved upmarket.

2. Shifting supply chains: New partners and growing concentration risks

2.1 The United States remains the dominant supplier but its share is eroding

The United States has consistently been the EU's largest source of imports for this product category, accounting for €1.15 billion in 2015 and €1.34 billion in 2025. However, its share of total imports has declined as other partners have grown more rapidly. The US's import growth of 16.2% over the decade is modest compared to the market average, reflecting its already large base.

2.2 Costa Rica, Singapore, and China have emerged as fast-growing import sources

The most dramatic changes in the EU's import landscape involve a handful of fast-growing partners:

Costa Rica's rise is particularly notable. The country has become a significant hub for medical device manufacturing — partly driven by favourable trade agreements and the presence of major multinational implant manufacturers. Singapore's growth similarly reflects its role as a strategic location for high-tech medical device production. China's near-ninefold increase, while still from a small base, signals the country's growing ambitions in advanced medical technologies.

2.3 Import concentration has decreased, suggesting geographic diversification

The Herfindahl-Hirschman Index (HHI) for imports fell from 4,906 to 3,029 (−38.3%), indicating a meaningful reduction in import concentration. While the US remains dominant, the growth of Costa Rica, Singapore, Mexico, and others has diversified the EU's supply base. However, an HHI of 3,029 still implies a moderately concentrated market — the US alone accounts for roughly half of all imports by value.

2.4 Export partners have also shifted, with the UK becoming the top destination

On the export side, the United Kingdom has overtaken the United States as the EU's largest export destination, growing from €155.5 million to €462.5 million (+197.5%). This likely reflects both the UK's strong healthcare sector (NHS) and the post-Brexit trade reorientation, where direct exports from the EU replaced previous intra-EU flows. China (+76.3%) and Russia (+176.3%) also emerged as increasingly important export markets. By contrast, exports to Brazil declined slightly (−9.3%), and Switzerland remained roughly stable.

3. The Netherlands as Europe's medical implant hub — and the role of intra-EU restructuring

3.1 The Netherlands dominates EU trade flows in both directions

A striking feature of the data is the outsized role of the Netherlands. In 2025, the Netherlands accounted for €2.00 billion in extra-EU imports and €1.53 billion in extra-EU exports — representing 75% and 58% of total EU trade in this product, respectively. Both figures have more than doubled since 2015 (imports +180.4%, exports +113.2%).

This dominance is almost certainly explained by the Netherlands' role as a logistics and distribution hub for the medical device industry. Major multinationals (Medtronic, Johnson & Johnson, Stryker, and others) operate their European distribution centres in the Netherlands, taking advantage of the Port of Rotterdam, Schiphol Airport, and favourable tax arrangements. Trade is therefore recorded as entering and leaving the EU through the Netherlands, even when the final destination or origin is another member state.

3.2 Other EU member states show varied and often declining trade positions

The sharp decline in France's recorded imports (−82.3%) and Ireland's (−61.5%) likely reflects supply chain centralisation rather than a genuine decline in consumption. As multinational firms consolidate distribution in the Netherlands and Belgium, import declarations shift accordingly, even though the products ultimately reach patients across the EU.

3.3 EU domestic production has expanded dramatically

EU production of artificial body parts grew from an estimated €977.6 million in 2015 to €4.0 billion in 2025 — an increase of 309.2%. This surge in production, which outpaces both import and export growth, suggests that the EU has significantly expanded its manufacturing base for medical implants over the decade. This could be driven by reshoring trends, investment in advanced manufacturing (e.g., 3D-printed implants), and the growing needs of an ageing European population.

3.4 The Netherlands and Ireland show the strongest export specialisation

Looking at revealed comparative advantage (RCA), the Netherlands (RCA = 4.55) and Ireland (RCA = 2.69) stand out as the most specialised EU exporters in this product category. Ireland's specialisation likely reflects the presence of major medical device manufacturers (Medtronic, Boston Scientific) with significant production facilities there. At the other end, countries like Estonia, Romania, Finland, and Denmark show very low RCA values, indicating minimal involvement in this sector.

Conclusion

Over the period 2015–2025, the EU market for artificial body parts (CN 90213990) underwent a fundamental transformation. The Union moved from a net import position to approximate trade balance, driven by robust export growth (+79.4% in value) and a significant expansion of domestic production (+309.2%). Import volumes actually declined, even as import values rose — a sign that the EU's import basket has shifted towards higher-value, more specialised technologies.

Geographically, the trade landscape has been reshaped by the emergence of Costa Rica, Singapore, and China as increasingly important suppliers, and by the post-Brexit reorientation of EU–UK trade flows. The Netherlands has consolidated its position as Europe's dominant logistics hub for medical implants, accounting for three-quarters of extra-EU imports by 2025 — though this likely reflects distribution patterns more than final consumption.

The EU's growing export propensity (from 34.5% to 92.0%) and rising trade intensity (from 55.5% to 95.4%) confirm that this sector has become deeply integrated into global value chains. For policymakers, the key question going forward is whether the EU can sustain its competitive edge in an increasingly competitive global market — particularly as emerging economies build their own implant manufacturing capabilities — while managing the risks associated with supply chain concentration and geopolitical uncertainty.